In this March 16, 2020, file photo, a patient receives a shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle. (AP Photo/Ted S. Warren, File)
As the quest for a COVID-19 vaccine intensifies, companies at the forefront of research need to grapple with complex liability issues at all stages of the work, from the science of creating a safe and effective vaccine to the logistics of distribution and the management of risk.
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Anne Bagamery
Anne Bagamery is the Paris-based correspondent for Law.com International. She writes about lawyers and legal issues in France and elsewhere in Europe. Her coverage includes the business of law, global and domestic law firms, in-house legal departments and regulatory issues. She can be reached at [email protected] and on Twitter: @abagamery.
